PB1样铜绿假单胞菌噬菌体PHW2的生物学特性

【背景】铜绿假单胞菌(Pseudomonas aeruginosa)是一种引起医院感染、急性感染和慢性感染的常见条件致病菌。多重耐药铜绿假单胞菌仍然是引起严重医院感染的常见病菌,其临床治疗面临严峻挑战。噬菌体具有特异性杀菌的能力,在防治铜绿假单胞菌耐药菌方面具有应用前景。【目的】分离能裂解碳青霉烯类耐药的铜绿假单胞菌的噬菌体,分析其生物学特性和基因组特征,为噬菌体治疗储备资源。【方法】采集环境水样,用双层琼脂平板法分离噬菌体,对其形态、一步生长曲线、感染复数等生物学特性进行研究;使用IlluminaMiSeq平台测定噬菌体的全基因组序列,利用Newbler3.0、GeneMarkS、BLASTp、Mauve2.4.0等生物信息软件进行拼接、注释和比较基因组学分析。【结果】分离到一株噬菌体PHW2,该噬菌体属肌尾病毒科成员,可裂解7株碳青霉烯类耐药的铜绿假单胞菌;其最佳感染复数为0.1。一步生长曲线结果显示,其感染宿主菌PA001的潜伏期为100 min,裂解期为360 min,裂解量为25 PFU/cell;噬菌体PHW2在温度25-50℃和pH 6.0-8.0范围内稳定;紫外照射7 min后PHW2活性明显下降;5%氯仿处理100 min内,PHW2仍保持较高的活性。噬菌体PHW2的基因组长65 984 bp,GC含量为55.69%,编码92个ORFs,不含tRNA。基因组比对结果显示PHW2与PB1样噬菌体高度相似。体外生物被膜抑制试验和清除试验结果显示,噬菌体PHW2能显著抑制宿主菌PA001形成的生物被膜并破坏24 h内形成的生物被膜。【结论】分离鉴定了一株新的PB1样噬菌体PHW2,对碳青霉烯类耐药的铜绿假单胞菌裂解能力强。生物学特性、基因组特征、体外生物被膜抑制试验和清除试验结果表明该噬菌体具有治疗铜绿假单胞菌耐药菌的潜力。     

铜绿假单胞菌肺部感染小鼠模型中L-17A的表达研究

摘要：目的 了解铜绿假单胞菌肺部感染小鼠模型中L-17A（白介素-17）的表达,指导铜绿假单胞菌肺部感染治疗。方法 择取60只SPF级昆明白雌性小鼠为研究对象,应用随机平行对照法将其分成两组,对照组自小鼠气管内注入相同量的生理盐水,实验组自小鼠气管内注入铜绿假单胞菌悬液0.03 mL,造模后处死两组小鼠,将其肺部组织制制作病理切片,行HE染色,并应用免疫组化法检测肺组织IL-17A表达量变化情况。结果 于3 h、9 h和24 h后,实验组肺组织中IL-17A灰度（182.2±4.7,184.0±9.0,182.8±9.9）明显优于对照组（170.2±4.3,161.8±6.5,147.4±7.3）,且9 h、24 h后血清中IL-17A浓度（132.6±5.5,149.8±5.7）pg/mL显著高于对照组（124.2±2.8,123.2±7.9）pg/mL,差异具有统计学意义（P＜0.05）。结论 IL-17A经由炎症细胞募集介入铜绿假单胞菌肺部感染炎症反应,并参与了病原菌清除过程,临床上应引起足够重视。     

噬菌体治疗对铜绿假单胞菌诱导的肺炎小鼠细菌负荷和炎症水平的影响

铜绿假单胞菌是医院获得性感染和肺部感染的主要致病菌之一,能够引发患者烧伤部位、呼吸道和泌尿道的慢性和急性感染,导致严重的发病率和死亡率。由于抗生素的滥用,铜绿假单胞菌已经对多种抗生素表现出耐药性,严重限制了可用于治疗感染患者的治疗方案。噬菌体依靠内寄生活的细菌进行生存和繁殖,其结构简单,分布广泛,被发现能够用于治疗人类细菌感染疾病,是治疗由铜绿假单胞菌引发的感染的可能方案之一。本研究构建了铜绿假单胞菌诱导的肺炎小鼠模型,对模型小鼠进行噬菌体和美罗培南的单独和联合给药处理,采用ELISA和Western blotting等方法检测了小鼠血清,支气管肺泡灌洗液和肺组织中的细菌负荷、常规生化指标和炎症因子水平。表明经铜绿假单胞菌感染后的小鼠,肺组织的细菌负荷显著增加,血清CRP和乳酸升高,TNF-α、IL-1β、IL-6和透明质酸水平也都显著上升。噬菌体和美罗培南的单独或联合处理能显著下调这些上升,其中噬菌体单独使用对乳酸的下调作用最为显著,而联合用药则对下调血清IL-1β水平具有协同优势。     

一株感染铜绿假单胞菌的双链RNA噬菌体PaP6的分离和鉴定

【目的】鉴定一株新分离的铜绿假单胞菌噬菌体PaP6的生物学特性。【方法】利用铜绿假单胞菌临床分离株PA038为宿主,从西南医院污水中分离得到一株裂解性噬菌体PaP6,观察其噬斑特点;氯化铯密度梯度离心纯化噬菌体颗粒后,用透射电子显微镜观察噬菌体形态;提取PaP6基因组,通过DNA酶和RNA酶酶切,做基因组酶切图谱分析;按照感染复数(MOI)分别为10、1、0.1、0.01、0.001和0.000 1加入噬菌体和宿主菌,裂解细菌后,测定噬菌体滴度;以MOI=10的比例加入噬菌体和宿主菌,绘制一步生长曲线;用112株铜绿假单胞菌临床分离株检测PaP6宿主谱。【结果】PaP6的噬斑直径约2 mm-4 mm,圆形透明,边缘清晰;PaP6噬菌体呈多面体立体对称的头部,直径约45 nm;酶切图谱表明PaP6基因组对DNase不敏感,对RNase敏感,未酶切基因组具有3节段双链RNA(dsRNA),长度分别约为9.0、4.5、3.5 kb,共约17 kb;当MOI为0.1时PaP6感染其宿主菌产生的子代噬菌体滴度最高,达到3.4×109 PFU/m L;用一步生长曲线描绘了其生长特性;PaP6可以感染40.1%的临床分离株,是一株比较广谱的噬菌体。【结论】首次报道了一株铜绿假单胞菌的ds RNA分节段噬菌体,分类学上属于囊病毒科,该噬菌体具有较广的宿主谱,在噬菌体治疗领域具有应用前景。     

林麝源铜绿假单胞菌噬菌体vB＿PaeM＿PAMD02的生物学特性与全基因组序列分析

【背景】圈养林麝一半以上的死亡是由铜绿假单胞菌引起的化脓性疾病导致。另外,由于细菌的抗性增加,噬菌体是继抗生素后的另一抗菌选择。【目的】以分离自病死林麝肺脏的铜绿假单胞菌为宿主菌分离一株噬菌体,对其进行生物学特性、全基因组序列分析与体内抑菌试验。【方法】通过双层平板法分离纯化一株裂解性噬菌体,测定其裂解谱、最佳感染复数、一步生长曲线、热稳定性、最适生长pH等生物学特性,通过电镜观察其具体形态,进行全基因组测序与序列分析,并进行小鼠体内抑菌试验。【结果】分离到一株裂解性铜绿假单胞菌噬菌体并命名为vB＿PaeM＿PAMD02,该噬菌体具有透明且边缘清晰无晕环的噬菌斑,其裂解谱较窄,最佳感染复数为0.1,裂解潜伏期为40 min,裂解暴发量较高,热稳定性较高,可耐受弱碱环境。其全基因组大小为66 264 bp,GC含量为55.59%,序列注释结果显示该噬菌体具有92个开放阅读框,不含毒力与耐药基因,属于肌尾噬菌体科。小鼠体内抑菌试验结果显示了PAMD02对其宿主菌良好的抑菌效果。【结论】本研究分离的噬菌体PAMD02有较高的裂解效率,对不利环境有较好的耐受性,不含毒力基因与耐药基因,具有应用...     

PH826噬菌体与抗生素联用有效抑制多重耐药铜绿假单胞菌生物被膜的形成

【目的】铜绿假单胞菌(Pseudomonas aeruginosa)是一种重要的革兰氏阴性病原体,可以加重囊性纤维化患者的肺部感染,最终会导致患者的死亡。然而由于多重耐药(multi-drug resistant,MDR)和泛耐药(pan-drug resistant, PDR)铜绿假单胞菌菌株的出现,使其防控变得更为严峻。【方法】从养殖场污水中分离能有效裂解多重耐药铜绿假单胞菌的噬菌体,研究其形态特征、生物学特性、宿主谱范围、基因组特征和体外抑菌能力等,并采用噬菌体和抗生素联用的方法进行生物被膜的抑制试验。【结果】透射电子显微镜的形态分析和基因组分析结合表明,该噬菌体属于Nankokuvirus病毒属。生物学特性试验表明,PH826具有广泛的温度稳定性(4-60℃)和pH稳定性(3.0-11.0)。宿主谱测试显示,PH826可以裂解13株铜绿假单胞菌(包括人源和动物源),体外抑菌试验显示,PH826在感染复数(multiplicity of infection, MOI)分别为10、1、0.1时对铜绿假单胞菌均有强烈的裂解作用。根据基因组分析,PH826噬菌体的基因组大小为87 95...     

植物发酵液提取物对铜绿假单胞菌生物膜的作用

【目的】探讨植物发酵液提取物(plant fermentation extract,PFE)对铜绿假单胞菌生物膜的抑制作用,为临床上铜绿假单胞菌感染相关疾病的治疗提供参考。【方法】通过划线法分离临床标本中的铜绿假单胞菌并进行鉴定,通过报告菌株测定铜绿假单胞菌的毒力因子,采用试管法和激光共聚焦扫描显微镜测定生物膜的形成。【结果】在分离出的16株铜绿假单胞菌中,PFE对PA007菌株的作用效果最好,1%PFE显著降低PA007菌株生物膜、绿脓菌素和N-(3-oxododecanoyl)-HSL(3-oxo-C12-HSL)的产量(P0.05)。同时,也显著降低Las A蛋白酶的活性以及持留菌存活率(P0.05)。荧光定量PCR实验结果表明PFE能显著抑制las I和pqs A基因的表达(P0.05)。【结论】PFE具有抗铜绿假单胞菌感染能力,在临床上铜绿假单胞菌感染疾病的治疗中具有巨大的潜在价值。     

A类Ⅰ型清道夫受体调节小鼠腹腔巨噬细胞抗肺炎克雷伯菌和铜绿假单胞菌感染

本研究旨在探讨A类Ⅰ型清道夫受体(scavenger receptor class A type Ⅰ,SR-AI)在呼吸道感染常见病原体肺炎克雷伯菌及铜绿假单胞菌感染过程中的免疫调节功能。以肺炎克雷伯菌和铜绿假单胞菌临床分离株与野生型小鼠和SR-AI~(-/-)小鼠腹腔原代巨噬细胞互作,研究SR-AI在吞噬和炎症反应中的作用。荧光染料染色菌体及检测胞内荧光强度,数据显示SR-AI敲除后巨噬细胞对肺炎克雷伯菌的吞噬能力下降,但对铜绿假单胞菌的吞噬能力升高。采用实时定量荧光聚合酶链反应检测相关炎症因子mRNA水平,发现SRAI敲除后肺炎克雷伯菌和铜绿假单胞菌刺激巨噬细胞引发的炎症反应均增强。结果表明,SR-AI参与巨噬细胞对肺炎克雷伯菌的吞噬,但不参与对铜绿假单胞菌的吞噬,且可能抑制了肺炎克雷伯菌和铜绿假单胞菌引发的炎症反应。     

不同感染途径致大鼠肺炎模型制备的比较

目的探索铜绿假单胞菌致大鼠肺炎模型的制备方法,为后续研究奠定实验基础。方法将Sprague-Dawley(SD)大鼠48只随机分为4组:A对照组、B气管注射组、C气管插管感染组和D滴鼻感染组。适应饲喂3 d后,分别给予不同造模干预,分别于干预后5、10和15 d动态监测各亚组大鼠体重、体温、白细胞数、肺组织病理学变化等。结果各模型组大鼠行为学表现、体重、体温、白细胞、肺组织炎症病理学表现均与对照组差异有显著性;(2)各模型组均证实为铜绿假单胞菌感染,对照组则阴性。结论经滴鼻途径以铜绿假单胞菌感染大鼠,可得到合格大鼠肺炎模型;此感染途径可避免手术创口带来的炎症反应干扰,简便易行,可推广。     

铜绿假单胞菌菌苗预防白色念珠菌感染的实验研究

目的利用铜绿假单胞菌菌苗探索阻断白色念珠菌感染的影响。方法家兔耳皮内注射白色念珠菌,进行活菌攻击,建立动物感染模型。观察用铜绿假单胞菌菌苗免疫的家兔状况;用试管凝集法测定家免的抗体效价;采用小白鼠体内吞噬法测定免疫组和空白对照组巨噬细胞的吞噬百分率和吞噬指数,以得出铜绿假单胞菌菌苗的免疫性。结果观察发现：与对照组比较,铜绿假单胞菌菌苗免疫组抗体效价,巨噬细胞的吞噬能力明显提高;注射区局部感染及全身症状明显减轻;肾脏感染灶减少,病理切片显示病情较轻。结论铜绿假单胞菌菌苗能够减轻注射区局部感染及全身症状,对肾脏的播散性白色念珠菌感染具有一定的阻断作用。     

<Emphasis Type="Italic">Salmonella typhimurium</Emphasis> engineered to produce CCL21 inhibit tumor growth

Intravenously-applied bacteria tend to accumulate in tumors and can sporadically lead to tumor regression. Systemic administration of attenuated Salmonella typhimurium is safe and has shown no significant adverse effects in humans. The purpose of this study was to test the hypothesis that engineering S. typhimurium to express a chemokine, CCL21, would increase anti-tumor activity. We engineered an attenuated strain of S. typhimurium to produce the chemokine CCL21. Attenuated S. typhimurium expressing CCL21 significantly inhibited the growth of primary tumors and pulmonary metastases in preclinical models of multi-drug-resistant murine carcinomas, while control bacteria did not. Histological analysis of tumors showed marked inflammatory cell infiltrates in mice treated with CCL21-expressing but not control bacteria. Levels of cytokines and chemokines known to be induced by CCL21 [e.g., interferon-γ (INFγ), CXCL9, and CXCL10] were significantly elevated in tumors of mice treated with CCL21-expressing but not control S. typhimurium. The anti-tumor activity was found to be dependent on CD4- and CD8-expressing cells, based on antibody-mediated in vivo immuno-depletion experiments. Anti-tumor activity was achieved without evidence of toxicity. In summary, chemokine-expressing, attenuated bacteria may provide a novel approach to cancer immunotherapy for effective and well-tolerated in vivo delivery of immunomodulatory proteins. Markus Loeffler and John C. Reed should be considered senior authors.     

噬菌体治疗肺炎克雷伯菌感染的研究进展

随着细菌的进化以及部分抗生素的滥用，耐药细菌的感染已成为21世纪主要的公共卫生挑战之一。其中，耐药肺炎克雷伯菌(Klebsiella pneumoniae)问题尤为突出。噬菌体在治疗耐药细菌感染引起的疾病方面展现出一定的潜力及独特优势，但目前噬菌体治疗尚缺乏统一的临床指导规范。虽然临床上有少数将噬菌体用于治疗肺炎克雷伯菌感染的成功案例，但多数情况下是采用噬菌体配合抗生素疗法，噬菌体在其中的作用仍不明确。本文综合评述国内外研究数据，回顾与噬菌体治疗肺炎克雷伯菌感染相关的数个重点问题，包括噬菌体的特性以及影响其疗效的因素，旨在为肺炎克雷伯菌和其他耐药细菌的噬菌体治疗提供参考。     

水产动物副溶血弧菌病及其噬菌体防治研究进展

副溶血弧菌是水产动物弧菌病的重要病原微生物之一,又是食源性致病菌,摄入被其污染的水产品后可引发肠胃炎、败血症和坏死性筋膜炎等疾病,对水产养殖业及公共卫生安全均具有较大威胁。抗生素大量使用甚至滥用,不可避免地会带来水产品药物残留和细菌耐药等问题,开发安全有效的抗生素替代品迫在眉睫。作为细菌病毒,噬菌体具有宿主特异性强、易筛选、易保存、高效直接等优点,在水产养殖病害防控和食品安全领域受到广泛关注。本文概述了水产动物的副溶血弧菌病及该菌噬菌体防治的研究进展,为副溶血弧菌噬菌体及制剂应用于水产养殖病害生物防控提供参考。     

噬菌体治疗肺炎克雷伯菌感染的研究进展

肺炎克雷伯菌是肠杆菌科家族中的一员,在各种环境中广泛存在,可导致诸如奶牛乳房炎在内的多种动物疫病,引起人类的肺炎、尿路感染、菌血症、伤口性感染和化脓性脓肿在内的多种临床感染。该菌对抗生素的耐受日趋严重,而且高毒力菌株不断出现,给该菌的防控带来了巨大挑战。噬菌体是一种裂解细菌的病毒,因其具有治疗耐药细菌感染的潜力而备受关注,世界各地均有使用噬菌体成功治疗耐药细菌感染的案例。本文基于国内外对肺炎克雷伯菌及其噬菌体的研究数据,综述了肺炎克雷伯菌的流行病学调查情况和噬菌体在治疗肺炎克雷伯菌感染方面的应用,以期为基于肺炎克雷伯菌噬菌体的抗菌研究和临床应用提供参考。     

纳米材料治疗具核梭杆菌促进的结直肠癌研究进展

具核梭杆菌(Fusobacterium nucleatum,Fn)是一种口腔厌氧菌,最近被发现在人类结直肠癌(colorectal cancer,CRC)细胞表面聚集,其富集程度与癌症治疗预后呈高度负相关。大量研究表明,Fn参与CRC的发生与发展过程,Fn与肿瘤微环境中多种组分相互作用从而增强肿瘤的耐药性。近年来,开始有研究利用纳米材料抑制Fn在肿瘤部位的增殖或通过直接靶向Fn治疗CRC。因此,本综述一方面将对近年来Fn在CRC中促肿瘤的机制进行梳理总结,另一方面将归纳整理不同纳米材料应用于Fn相关CRC治疗的最新研究进展,最后对纳米材料在Fn介导的CRC治疗中的应用前景进行了展望。     

Measurement of serum levels of natalizumab, an immunoglobulin G4 therapeutic monoclonal antibody

Chlorophyllide a is a metabolite late in the biosynthesis of chlorophylls and bacteriochlorophylls. Isolation procedures for chlorophyllide a from Rhodobacter capsulatus CB1200 and barley (Hordeum vulgare L.) are described and compared. R. capsulatus CB1200 is a double mutant in the bacteriochlorophyllide a biosynthetic pathway, and chlorophyllide a is excreted by the cells when grown in Tween 80-containing liquid medium. It was purified by liquid or solid phase extraction, yielding 7 mg of chlorophyllide a from 1 L of culture. In a second approach, intrinsic chlorophyllase activity was used to dephytylate chlorophyll in an acetonic preparation of leaves of wild-type or chlorophyll b-deficient barley. Purification was achieved by liquid phase extraction, yielding 14 μg of chlorophyllide a per gram of barley leaves. Chlorophyllide a was identified by thin layer chromatography, absorption spectroscopy, and mass spectrometry.     

Evaluation of two vaccines for the treatment of pythiosis insidiosi in horses

Two vaccines to treat pythiosis insidiosi in horses were evaluated in 71 Costa Rican horses between 1982 to 1988. One vaccine used a cell-mass (CMV) as antigen and the other a soluble concentrated antigen (SCAV). Both vaccines cured horses infected with Pythium insidiosum (p value 14%). The age of lesions prior to vaccination was important in the response of the horses to immunotherapy. All horses with lesions 0.5 months or less in duration were cured regardless of the vaccine used. Horses with lesions two or more months old did not respond to either vaccine. The age of the horses did not have any influence on their response to the vaccinations. The CMV produced a prominent inflammatory reaction at the side of injection, while the SCAV gave a low inflammatory reaction. In addition, the CMV lost its effectiveness two to three weeks after its preparation. By contrast, the SCAV maintained its ability to cure horses even after 18 months. Immunotherapy using SCAV can thus be used as the vaccine of choice in early cases of equine cutaneous pythiosis insidiosi.Private practice     

Phage therapy of coral disease

At present there are no known procedures for preventing or treating infectious diseases of corals. Toward this end, the use of phage therapy has been investigated. Lytic bacteriophages (phages) were isolated for two bacterial pathogens that are responsible for coral diseases, Vibrio coralliilyticus, which is the causative agent of bleaching and tissue lysis of Pocillopora damicornis, and Thalosomonas loyaeana, which causes the white plague-like disease of Favia favus. By using these phages in controlled aquaria experiments, it was demonstrated that each of these diseases could be controlled by the pathogen-specific phage. The data indicate that initially the phages bind to the pathogen in seawater and are then brought to the coral surface where they multiply and lyse the pathogen. The phages remained associated with the coral and could prevent subsequent infections. These data suggest that phage therapy has the potential to control the spread of infectious coral diseases.     

Antisense Downregulation of the Apoptosis-related Bcl-2 and Bcl-xL Proteins: A New Approach to Cancer Therapy

Members of the bcl-2 family genes are thought to be central regulators of apoptosis. Overexpression of antiapoptotic proteins, such as Bcl-2 and Bcl-xL, contributes not only to the development of cancer but also to its resistance against a wide variety of anticancer agents. Thus, downregulation of Bcl-2 and Bcl-xL can potentially be used to improve therapeutic approaches to advanced cancer. The use of antisense biotechnology to downregulate antiapoptotic bcl family members in diverse cancers in vitro and in vivo is reviewed. The effects and potential limitations of antisense strategies are also discussed in the context of a critical view of recent research in the field.     

In Vivo Gene Electroporation of Glial Cell Line-Derived Neurotrophic Factor (GDNF) into Skeletal Muscle of SOD1 Mutant Mice

Motor neurons degenerate with intracellular vacuolar change and eventually disappear in spinal cords of SOD1 mutant mice, resembling human amyotrophic lateral sclerosis (ALS). The GDNF gene was electroporatically transferred into the leg muscles of SOD1 mutant mice and expressed in muscle cells. This gene therapy with GDNF delayed the deterioration of motor performance, being retrogradely transported into spinal motor neurons. However, the number of the motor neurons and survival of the mutant mice were not improved by GDNF treatment. These results indicate that in vivo gene electroporation of GDNF into muscles could be an appropriate therapeutic approach to ameliorate an early dysfunction of motor neurons in SOD1 mutant mice, but further improvement is needed to use this gene transfer as an effective treatment of ALS.